SCHEMBL6436153

SCHEMBL6436153

Nc1nc2nonc2nc1N/N=C/c1cc(Cl)ccc1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.42
MEN1 O00255 9/20 0.42
POLB P06746 4/20 0.42
MAPT P10636 3/20 0.42
GAA P10253 3/20 0.42
KDM4E B2RXH2 5/20 0.42
RAB9A P51151 4/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
NPC1 O15118 2/20 0.42
MITF O75030 1/20 0.42
GPR174 Q9BXC1 1/20 0.42
ALDH1A1 P00352 2/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
KDM1A O60341 1/20 0.41
PABPC1 P11940 1/20 0.40
HTT P42858 4/20 0.40
TDP1 Q9NUW8 1/20 0.40
DDX3X O00571 1/20 0.40
LMNA P02545 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6436156 1.00 KMT2A (0.42) KMT2AMEN1POLBMAPTGAA
SCHEMBL6422145 0.83 GAA (0.55) KMT2AMEN1POLBMAPTGAA
SCHEMBL6422141 0.83 GAA (0.55) KMT2AMEN1POLBMAPTGAA
SCHEMBL6416317 0.82 MAPT (0.45) KMT2AMEN1POLBMAPTGAA
SCHEMBL6418357 0.81 MAPT (0.47) KMT2AMEN1POLBMAPTGAA
SCHEMBL6413346 0.81 GAA (0.52) KMT2AMEN1POLBMAPTGAA
SCHEMBL6418421 0.81 SMN1; SMN2 (0.44) KMT2AMEN1POLBMAPTKDM4E
SCHEMBL6417113 0.80 DDX3X (0.57) KMT2AMEN1POLBMAPTGAA
SCHEMBL6417108 0.80 DDX3X (0.57) KMT2AMEN1POLBMAPTGAA
SCHEMBL6419259 0.79 SMN1; SMN2 (0.42) KMT2AMEN1POLBMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 KMT2A 3640/4885MEN1 4392/4885POLB 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.